Federer Got a Standing Ovation for His Farewell. Serena Gets Suspicion for Her Comeback. — Sports' Double Standard
The decision to grant Serena Williams a singles wild card for Wimbledon 2026 has fractured the tennis world along familiar fault lines, raising simultaneous questions about wild card legitimacy, GLP-1 drug policy in sport, and a decades-long pattern of subjecting Williams' body to scrutiny that comparable male legends have never faced. Williams, 44, has not competed in singles since a third-round exit at the 2022 US Open, yet the All England Club extended both singles and doubles wild cards for the June 29 tournament opener. The revelation that Williams used Zepbound, a GLP-1 receptor agonist, to lose 34 pounds intensified the debate — despite WADA classifying GLP-1 agents only on its monitoring list, not as prohibited substances, with a final ruling expected between late 2026 and early 2027. A direct comparison between the global celebration of Federer's 2022 Laver Cup farewell and the suspicion directed at Williams' comeback exposes a structural asymmetry that has tracked her career for over two decades: the target of criticism never changes, only the angle of attack. This moment is less about one wild card or one medication and more about what sport still believes regarding whose body is permitted to evolve, age, and return on its own terms.